CHD1Li 6.11, a potent oncogenic chromodomain helicase DNA binding protein 1 like (CHD1L) inhibitor and an orally bioavailable antitumor agent, shows the enzymatic inhibition of the catalytic CHD1L (cat-CHD1L) recombinant protein with IC50 of 3.3 µM, and significantly reduces the tumor volume of colorectal cancer (CRC) xenografts generated from isolated quasi mesenchymal cells (M-Phenotype).